Jasper refiles Kira pro formas: $149M asset deal, $125M IPR&D charge, $132M PIPE nets $125M

Jasper Therapeutics, Inc.

Merger closed July 16, 2026: Jasper issued 5,195,009 Kira common shares at $0.774 and 4,644,977 preferred shares, total consideration ~$149.0M including $1.34M deal costs.
Deal treated as an asset acquisition under ASC 805-50 with no goodwill; $125.2M of acquired IPR&D (KP-104 anti-C5 x Factor H and KP-701 anti-CD79B x CD32B) expensed at closing.
PIPE financing: 4,655,951 preferred shares sold for ~$132.0M, closed July 20, 2026; net proceeds $124.8M after $6.98M placement agent fees; pro forma cash $142.8M at June 30, 2026.
Mirador license (July 13, 2026) grants exclusive worldwide rights to KP-301 and KP-402: $12.0M upfront, $8.0M on delivery, up to $108.5M development and $350.0M commercial milestones.
Pro forma FY2025 net loss $206.8M vs Jasper's stand-alone $75.8M; each pre-close common share gets one CVR paying pro-rata $30.0M if FDA grants a briquilimab Priority Review Voucher by Dec 31, 2028.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.